VolitionRx Limited has announced proof-of-concept data from a blinded validation cohort demonstrating over 95% sensitivity for stage I and II cancers with 95% specificity using its Capture-Seq liquid biopsy technology. The study, which included 81 subjects, showed detection rates of 94% for stage I and 96% for stage II cancers, with overall sensitivity of 93% and specificity of 95%.
The company's Capture-Seq technology is designed to enrich and purify circulating tumor DNA for analysis and may support applications in multi-cancer early detection and minimal residual disease monitoring. This represents a significant advancement in the field of epigenetics, where Volition has focused its research and development efforts. The company maintains research activities in Belgium with additional facilities in the U.S. and London.
For business leaders and technology investors, the implications are substantial. Volition noted the technology targets an estimated $36 billion total addressable market and is currently the subject of discussions with potential licensing and diagnostic partners to accelerate development and commercialization. The company's dedication to developing simple, easy to use, cost-effective blood tests could transform cancer screening protocols worldwide.
The potential impact on healthcare systems and patient outcomes cannot be overstated. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. For more information about Volition's technology and research, visit https://volition.com/.
From an industry perspective, this development represents a significant step forward in liquid biopsy technology, which has been gaining traction as a less invasive alternative to traditional tissue biopsies. The high sensitivity and specificity rates reported in this study suggest that Capture-Seq could become a valuable tool in the early detection arsenal, potentially enabling earlier intervention and better treatment outcomes.
The announcement was distributed through InvestorWire, a specialized communications platform that provides wire-grade press release syndication for private and public companies. For more information about their services, visit https://www.InvestorWire.com.
